Patents by Inventor Paul D. Kessler
Paul D. Kessler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11083704Abstract: The disclosed subject matter provides methods of using nitroxyl donating compounds and pharmaceutical compositions comprising such compounds in a dose escalation regimen.Type: GrantFiled: January 2, 2018Date of Patent: August 10, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Paul D. Kessler, William R. Ewing, Maria Borentain, Tushar Garimella, Elyse G. Stock
-
Publication number: 20190343790Abstract: The disclosed subject matter provides methods of using nitroxyl donating compounds and pharmaceutical compositions comprising such compounds in a dose escalation regimen.Type: ApplicationFiled: January 2, 2018Publication date: November 14, 2019Inventors: Paul D. Kessler, William R. Ewing, Maria Borentain, Tushar Garimella, Elyse G. Stock
-
Publication number: 20120123186Abstract: The invention provides a method for treating locally advanced resectable esophageal cancer in a human comprising (a) administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding a human TNF-? and operably linked to a promoter, wherein the dose comprises about 4×107 to about 4×1012 particle units (pu) of adenoviral vector, at least once in a therapeutic period comprising up to about 10 weeks, (b) administering a dose of ionizing radiation to the human over the duration of the therapeutic period, and (c) administering a dose of one or more chemotherapeutics to the human over the duration of the therapeutic period, whereby the locally advanced resectable esophageal cancer in the human is treated.Type: ApplicationFiled: December 29, 2011Publication date: May 17, 2012Applicant: GENVEC, INC.Inventors: Paul D. Kessler, Henrik S. Rasmussen, Karen W. Chu
-
Publication number: 20110034752Abstract: The invention provides a method for treating cancer in a human comprising (a) administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding a human TNF-? and operably linked to a promoter, wherein the dose comprises about 4×107 to about 4×1012 particle units (pu) of adenoviral vector, at least once in a therapeutic period comprising up to about 10 weeks, (b) administering a dose of ionizing radiation to the human over the duration of the therapeutic period, and (c) administering a dose of one or more chemotherapeutics to the human over the duration of the therapeutic period, whereby the cancer in the human is treated.Type: ApplicationFiled: September 1, 2010Publication date: February 10, 2011Applicant: GENVEC, INC.Inventors: Paul D. KESSLER, Henrik S. RASMUSSEN, Karen W. CHU
-
Patent number: 7829078Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: July 15, 2008Date of Patent: November 9, 2010Assignees: Genzyme Corporation, Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 7704492Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: July 15, 2008Date of Patent: April 27, 2010Assignee: Genzyme CorporationInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20090208459Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: July 15, 2008Publication date: August 20, 2009Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20080305084Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: July 15, 2008Publication date: December 11, 2008Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20080199442Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: June 22, 2007Publication date: August 21, 2008Applicants: Genzyme Corporation, Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 7238674Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: March 5, 2002Date of Patent: July 3, 2007Assignee: Genzyme CorporationInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20030219415Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: May 23, 2003Publication date: November 27, 2003Applicants: Johns Hopkins University, Avigen, Inc.Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 6610290Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: October 1, 2001Date of Patent: August 26, 2003Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20030027751Abstract: The invention provides therapeutic fusion proteins which include a first peptide portion comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. Further provided are polynucleotides encoding such fusion proteins, vectors including such polynucleotides, methods of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing using such proteins, polynucleotides, and vectors.Type: ApplicationFiled: April 10, 2001Publication date: February 6, 2003Applicant: GenVec, Inc.Inventors: Imre Kovesdi, Paul D. Kessler
-
Publication number: 20020155608Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: October 1, 2001Publication date: October 24, 2002Applicant: Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20020147172Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: March 5, 2002Publication date: October 10, 2002Applicant: Avigen, Inc.Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 6335011Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: September 28, 1999Date of Patent: January 1, 2002Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Publication number: 20010001661Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: ApplicationFiled: January 4, 2001Publication date: May 24, 2001Applicant: Avigen, Inc.Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 6211163Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: May 10, 1999Date of Patent: April 3, 2001Assignee: Avigen, Inc.Inventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 5962313Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: January 16, 1997Date of Patent: October 5, 1999Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman
-
Patent number: 5858351Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.Type: GrantFiled: January 18, 1996Date of Patent: January 12, 1999Assignees: Avigen, Inc., Johns Hopkins UniversityInventors: Gregory M. Podsakoff, Paul D. Kessler, Barry J. Byrne, Gary J. Kurtzman